{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "16 mice received 50 \u03bcg 6G5j-IR700DX via the tail vein 24 h before surgery and were randomized to two groups: FGS-only ( n = 8) and FGS + PIT ( n = 8)."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized to two groups: FGS-only ( n = 8) and FGS + PIT ( n = 8)."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "randomized to two groups"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "randomized to two groups: FGS-only ( n = 8) and FGS + PIT ( n = 8)."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The metastatic recurrence rate was 100.0% for FGS-only and 25.0% for FGS + PIT ( p = 0.007). The average total recurrent tumor weight was 2370.3 \u00b1 1907.8 mg for FGS-only and 705.5 \u00b1 1200.0 mg for FGS + PIT ( p = 0.039)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 7,
    "max_score": 25
  },
  "model": "gpt-4o"
}